Related Experiment Video
Updated: May 27, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Immunosuppressive therapy for autoimmune bullous diseases
1Department of Dermatology, Universitäts Allergie Centrum am Universitätsklinikum Dresden, Germany. Michael.Meurer@uniklinikum-dresden.de
Clinics in Dermatology
|December 6, 2011
Summary
Mycophenolate mofetil offers a safer alternative to azathioprine for autoimmune bullous diseases. Further research is needed to compare cyclophosphamide with newer treatments like rituximab.
Area of Science:
- Immunodermatology
- Pharmacology
Background:
- Adjuvant immunosuppressive drugs are crucial for managing autoimmune bullous diseases (AIBD) and minimizing corticosteroid side effects.
- Azathioprine and mycophenolate mofetil are common choices, with differing safety profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of adjuvant immunosuppressive drugs in AIBD management.
- To compare mycophenolate mofetil with azathioprine and discuss the role of cyclophosphamide and newer agents.
Main Methods:
- Comparative review of existing literature on immunosuppressive therapies for AIBD.
- Analysis of drug efficacy, myelosuppression, and hepatotoxicity.
Main Results:
- Mycophenolate mofetil and azathioprine show similar efficacy with oral corticosteroids in bullous pemphigoid and pemphigus vulgaris.
- Mycophenolate mofetil demonstrates a better safety profile (less myelosuppression and hepatotoxicity) than azathioprine.
- Cyclophosphamide remains relevant for severe, relapsing AIBD, with pulsed regimens showing promise.
Conclusions:
- Mycophenolate mofetil or its enteric-coated form may replace azathioprine as a preferred first-line adjuvant for moderate to severe AIBD.
- Randomized controlled trials are necessary to compare cyclophosphamide with novel treatments like rituximab and immunoapheresis and to optimize current therapies.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.